The estimated Net Worth of Leaf Venture Management Iii... is at least $22.5 Mille dollars as of 25 June 2018. Leaf Iii owns over 250,000 units of Aptinyx Inc stock worth over $22,469 and over the last 6 years Leaf sold APTX stock worth over $0.
Sign up
Leaf Iii APTX stock SEC Form 4 insiders trading
Leaf has made over 1 trades of the Aptinyx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Leaf bought 250,000 units of APTX stock worth $4,000,000 on 25 June 2018.
The largest trade Leaf's ever made was buying 250,000 units of Aptinyx Inc stock on 25 June 2018 worth over $4,000,000. On average, Leaf trades about 250,000 units every 0 days since 2018. As of 25 June 2018 Leaf still owns at least 368,345 units of Aptinyx Inc stock.
You can see the complete history of Leaf Iii stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Leaf Iii's mailing address?
Leaf's mailing address filed with the SEC is Manhattan, NY 10036, USA.
Insiders trading at Aptinyx Inc
Over the last 6 years, insiders at Aptinyx Inc have traded over $0 worth of Aptinyx Inc stock and bought 10,337,357 units worth $55,328,087 . The most active insiders traders include Street Partners Llc Adams, Patrick G Enright e James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of $18,161. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth $50,091.
What does Aptinyx Inc do?
welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
What does Aptinyx Inc's logo look like?
Complete history of Leaf Iii stock trades at Aptinyx Inc
Aptinyx Inc executives and stock owners
Aptinyx Inc executives and other stock owners filed with the SEC include:
-
Norbert Riedel,
President, Chief Executive Officer, Director -
Ashish Khanna,
Chief Financial Officer, Chief Business Officer -
Andrew Kidd,
Chief Operating Officer -
Dr. Norbert G. Riedel,
Exec. Chairman -
Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
CEO, Pres & Director -
Ashish Khanna,
CFO & Chief Bus. Officer -
Henry Gosebruch,
Independent Director -
Rachel Sherman,
Independent Director -
Robert Hombach,
Independent Director -
Patrick Enright,
Independent Chairman of the Board -
Adam Koppel,
Independent Director -
Elisha Gould,
Independent Director -
Tim Noffke,
VP of Program Management & Chief of Staff -
Dr. Harald Murck M.D., Ph.D.,
VP of Clinical & Medical Affairs -
Patrick Flavin,
Sr. Mang. of Corp. Devel. & Investor Relations -
Dr. Kathryn King Ph.D.,
Sr. VP of Clinical & CMC Operations -
Molly Dir,
VP of HR -
Juan Estupinan,
VP of Fin. & Accounting and Controller -
Capital Life Sciences Inves...,
-
Gilmore Neil O'neill,
-
Terry P Gould,
-
Leaf Venture Management Iii...,
-
David Houck,
Chief Development Officer -
Torsten M. Madsen,
Chief Medical Officer -
James N Topper,
Director -
Life Sciences Viii, L.P.Fhm...,
-
Capital Partners Ii, Llc Ta...,
-
Wilbur H Gantz,
Director -
Joseph R. Moskal,
Chief Scientific Officer -
Street Partners Llc Adams,
10% owner -
Liam Ratcliffe,
Director -
Joan W. Miller,